SynthesisPeerJ2025
Outcomes of stereotactic body radiotherapy for unresectable cholangiocarcinoma: a meta-analysis and systematic review.
Synthesis in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- External Beam Radiation Therapy for Intrahepatic Cholangiocarcinoma.Journal of gastrointestinal cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stereotactic body radiotherapy (SBRT) is an effective treatment for various malignancies. This meta-analysis aimed to determine the prognostic outcomes and toxicities of SBRT for unresectable cholangiocarcinoma (CC) using the most recent evidence. Methods: The review protocol was registered on PROSPERO (CRD42023393642). We searched PubMed, EMBASE, and the Cochrane Library for studies involving SBRT and CC. Study endpoints included median overall survival (OS), 1- and 2-year OS rates, 1- and 2-year disease control rates (DCR), and the incidence of grade 3 or higher toxicities. Results: Thirteen studies (366 patients) were included. Of these, 138 patients (37.7%) had extrahepatic CC and 228 patients (62.3%) had intrahepatic CC. The median total SBRT dose was 45 Gy, and the median biologically effective dose (BED Conclusions: This meta-analysis demonstrates that SBRT may be an efficacious and safe therapeutic option for unresectable CC. Further prospective studies comparing SBRT with alternative treatment approaches are required to define its definitive role in managing CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.